What Happened
More than 10,000 doses of retatrutide were intercepted at UK borders in the first nine months of 2026, up from six doses in all of 2025, according to seizure figures reported this week. Retatrutide is Eli Lilly's investigational triple agonist — GLP-1, GIP and glucagon receptors in one molecule — and it has picked up the nickname "Godzilla" in the grey market.
The concentration of the trade is the striking part. Retatrutide accounted for 93 per cent of every black-market weight-loss jab dose seized at UK borders this year. Seizures of all fake and unlicensed weight-loss injections rose from 435 doses in 2025 to 11,228 so far in 2026, and raids on illicit manufacturing sites produced a further 68,776 doses since the start of last year.
Laboratory checks on 72 suspect jabs since early 2025 found that 17 contained no weight-loss drug at all. Among the vials that did, labelled concentrations varied more than fourfold from lowest to highest — a spread wide enough that a buyer has no reliable way to know what is in the syringe.
The Medicines and Healthcare products Regulatory Agency repeated its standing warning that people should be extremely cautious when buying medicines online.
Who Is Affected
The immediate population is UK consumers buying injected weight-loss drugs through social platforms and messaging apps rather than a pharmacy. Sellers have moved openly onto TikTok, Instagram, Facebook and WhatsApp, where listings are cheap to post and easy to replace after takedown.
Secondary exposure falls on clinicians who inherit the consequences: patients presenting with unexplained hypoglycaemia or injection-site infections and no product history to offer. Testing laboratories are also absorbing volume, as buyers attempt to verify vials after delivery.
Timeline
- 2025: six retatrutide doses and 435 total weight-loss jab doses seized at UK borders.
- January–September 2026: more than 10,000 retatrutide doses and 11,228 total doses seized.
- 2025–2026: 68,776 additional doses recovered in raids on illicit manufacturing sites.
- November 1, 2026: seizure data reported publicly, alongside the MHRA caution.
What This Means for Researchers
Retatrutide has no approved finished product anywhere in the world; it remains in late-stage trials. That makes every retatrutide vial sold to a consumer, by definition, an unauthorised article with no manufacturing oversight behind it.
Two research implications stand out. Self-sourcing at this scale contaminates the evidence base — adverse events in unverified product cannot be attributed to the molecule, and reports of "retatrutide side effects" increasingly describe whatever a grey-market vial contained. And the speed of the grey market's shift toward an unapproved compound suggests demand is front-running regulatory review, which argues for earlier supply-chain monitoring rather than post-approval enforcement.
How to Verify Your Peptides
Independent testing is the only way to establish what a vial actually holds, and it has limits worth understanding.
- How peptide testing works — what a certificate of analysis covers and what it does not.
- HPLC vs LC-MS — why identity and purity require different instruments.
- Identity, purity and fill weight — the three measurements that catch most mislabelled product.
Match the batch number on any certificate to the batch number on the vial. A certificate for a different lot proves nothing about yours.
Safe Alternatives
Researchers can review the published evidence for the compounds in this class before considering any source: retatrutide, tirzepatide and semaglutide. For suppliers that document third-party testing, see our vendor directory.
Sources
Regulatory announcements — UK Medicines and Healthcare products Regulatory Agency. Industry reports — 2026 UK border seizure and illicit-manufacturing raid figures.